Tandem transplantation in lymphoma

Bone Marrow Transplantation

Volumn 28, Issue 6, 2001, Pages 529-535

  Papadopoulos, K P ^a   Noguera Irizarry, W ^a   Hesdorffer, C S ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Allogeneic; Autologous; Lymphoma; Tandem transplantation

Indexed keywords

BLEOMYCIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOFOS; ETOPOSIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; THIOTEPA; VINCRISTINE; VINDESINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MYOCARDITIS; PATIENT SELECTION; PRIORITY JOURNAL; RISK;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS;

EID: 0034769767     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703201     Document Type: Article

References (45)

1. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
2. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - A groupe d'Etude des Lymphomes de l'Adulte study
3. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
4. Long-term outcome of relapsed non-Hodgkin's lymphoma patients included in the PARMA trial: Incidence of late relapses, long-term toxicity and impact of the international prognostic index at relapse
5. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry
6. Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry
7. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Transplantation
8. High-dose therapy and autologous stem-cell transplantation vs conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: Results of a group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group
9. Updated analysis of patients with non-Hodgkin's lymphoma receiving either allogeneic or autologous transplants over a 12 year period
10. A prospective, comparative trial of allogeneic vs autologous stem cell transplantation for high risk lymphoma: Interim analysis
11. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial
12. The Hodgkin's disease prognostic index predicts outcome of autologous stem cell transplantation
13. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
14. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma
15. Two autotransplants for lymphoma - Acceptable toxicity (18%) of the second transplant and significant survival length in some patients. Data from the EBMT lymphoma registry
16. A predictive model for aggressive non-Hodgkin's lymphoma
17. MACOP-B treatment in diffuse large-cell lymphoma: Identification of prognostic groups in an Italian multicenter study
18. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma
19. Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high-intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin's lymphoma: An oligocentric report on 42 patients
20. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: A study by the non-Hodgkin's Lymphoma Co-operative Study Group
21. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma
22. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
23. Clinical outcome after front-line intensive sequential chemotherapy (ISC) in patients with aggressive non-Hodgkin's lymphoma and high-risk international prognostic index (IPI 3): Final analysis of survival in two trials
24. Failure of first-line induction high-dose chemotherapy in poor-risk patients with aggressive lymphoma: Updated results of the randomized LNH93-3 study
25. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma
26. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma
27. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation
28. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkin's disease or non-Hodgkin's lymphoma
29. Phase II study testing a double intensification in aggressive non-Hodgkin's lymphoma relapsing less than one year after initial treatment (PARMA2 study)
30. High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma
31. A novel regimen of tandem high dose therapy and autologous stem cell transplantation for poor risk lymphoma
32. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD)
33. Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect
34. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy
35. Mini-allografts: Ongoing trials in humans
36. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
37. Non-myeloablative conditioning limits transplant related mortality in patients who have previously failed high dose treatment
38. A non-myeloablative regimen with minimal non relapse mortality for allografting patients with Hodgkin's disease
39. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma
40. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease
41. Higher than expected transplant-related mortality and relapse following non-myeloablative stem cell transplantation for lymphoma adversely effects progression-free survival
42. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma
43. Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation after conditioning - Results of a phase 2 trial
44. A phase 1 study of recombinant human keratinocyte growth factor (rHuKGF) in lymphoma patients receiving high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation
45. Monoclonal antibodies and autologous stem cell transplantation for lymphoma